Cognitive function in Parkinson's disease. Francesco Le Pira Dipartimento di Neuroscienze Università di Catania.
Francesco Le Pira
Dipartimento di Neuroscienze
Università di Catania
20 patients with Parkinson's disease were tested for visuoperceptive disabilities and constructional apraxia versus a group of 20 controls. The visuoperceptive disabilities in the parkinsonians were relatively independent of mental deterioration, where present. The visuoperceptive disabilities were responsible for constructional apraxia.
“Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported with a propensity to bend the trunk forwards and to pass from a walking to a running pace: the senses and intellects being uninjured”.
in Parkinson disease
Aarsland D, Tandberg E, Larsen JP, Cummings JL.
Arch Neurol. 1996; 53:38-42
Approximately one quarter of the patients with PD had dementia with the motor manifestations of PD. Dementia was associated with depression, institutionalization, older age at onset of PD, and atypical neurologic features.
(Emre M., 2003)
Brown RG, Marsden CD.
Brain 1986; 109: 987-1002
Previous research on visuospatial function in Parkinson's disease is reviewed. The present experiment was designed to test two fundamental aspects of spatial ability, namely right-left discrimination and the manipulation of those concepts in different spatial perspectives. Measures of accuracy and reaction time were taken. The performance of patients with Parkinson's disease did not differ from that of normal subjects in the spatial components of the task. Neither a review of the literature, nor the results of the present study, give support to the idea of a generalized visuospatial deficit in Parkinson's disease.
23.9 ± 4.7
26.7 ± 4
10.8 ± 0.5
10.8 ± 0.4
12 ± 3.7
14.5 ± 2.3
1.1 ± 1.6
1.4 ± 1.8
California Verbal Learning Testversione ital. di G. Zappalà et. al.
I Maidment, C Fox, M Boustani
Cochrane Database of Systematic Reviews 2007 Issue 2
Rivastigmine appears to improve cognition and activities of daily living in patients with PDD. This results in clinically meaningful benefit in about 15% of cases. There is a need for more studies utilising pragmatic measures such as time to residential care facility and both patient and carer quality of life assessments. Future trials should involve other cholinesterase inhibitors, utilise tools to analyse the data that limit any bias and measure health economic factors. It is unlikely that relying solely on the last observation carried forward (LOCF) is sufficient. Publication of the observed case data in the largest trial would assist (Emre 2004). Adverse events were associated with the cholinergic activity of rivastigmine, but may limit patient acceptability as evidenced by the high drop out rate in the active arm.